Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K35/76

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/232527CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS IMMUNOGENIC COMPOSITIONS
WO 26.11.2020
Int.Class C12N 15/40
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
Appl.No PCT/CA2019/051592 Applicant UNIVERSITÉ LAVAL Inventor KOBINGER, Gary
The present disclosure relates to DNA vaccines against Crimean-Congo Hemorrhagic Fever (CCHF) virus. The present disclosure also relates to CCHF virus sequences and their use for vaccination such as DNA vaccination. The present disclosure more particularly relates to artificial nucleic acid molecules that are able to encode a CCHF polypeptide of an infectious CCHF virus, a fragment or a variant thereof. The nucleic acid molecules of the present application are formulated as immunogenic compositions.
2.WO/2020/234547NOVEL BACTERIOPHAGE STRAINS AND USES THEREOF
WO 26.11.2020
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/FR2020/050848 Applicant VETOPHAGE Inventor CHATAIN-LY, Mai Huong
The present invention relates to a composition comprising a bacteriophage strain or a mixture of bacteriophage strains selected from strains such as those stored at the CNCM under numbers CNCM I-5409, CNCM I-5410, CNCM I-5491 and CNCM I-5492. The invention also relates to the therapeutic use of said strains in humans and animals to treat S. aureus infections, in particular for treating mastitis in animals.
3.WO/2020/237044BACTERIOPHAGES FOR THE TREATMENT OF TUBERCULOSIS
WO 26.11.2020
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/US2020/033985 Applicant UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor HATFULL, Graham
The invention provides a composition (e.g., pharmaceutical composition) comprising a combination of two or more phages, wherein the phages are two or more of: (a) phage D29; (b) phage Adephagia∆41∆43; (c) phage Fionnbharth∆47; (d) phage Fred313cpm-1; and (e) phage MuddyHRMN0052-1; and a pharmaceutically acceptable carrier. The invention provides a method of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal comprising administering a pharmaceutical composition comprising a combination of two or more phages wherein the phages are two or more of: (a) phage D29; (b) phage Adephagia∆41∆43; (c) phage Fionnbharth∆47; (d) phage Fred313cpm-1; and (e) phage MuddyHRMN0052-1; and a pharmaceutically acceptable carrier. The composition can be administered alone or in combination with one or more antibiotics, wherein the length of treatment is reduced as compared to the length of treatment with one or more antibiotics alone.
4.WO/2020/233102PHARMACEUTICAL COMPOSITION FOR TREATMENT OF TUMOR OR CANCER, AND APPLICATION THEREOF
WO 26.11.2020
Int.Class A61K 35/766
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
766Rhabdovirus, e.g. vesicular stomatitis virus
Appl.No PCT/CN2019/123567 Applicant HANGZHOU EVERBRIGHT BIOLOGICS, LTD. Inventor QIN, Xiaofeng
Provided are a pharmaceutical composition for treatment of a tumor or cancer, and an application thereof. The pharmaceutical composition comprises an oncolytic rhabdovirus and a CD38 small molecule inhibitor such as rhein by means of direct local injection or systemic administration or intratumoral delivery. The oncolytic rhabdovirus has the property of recognizing tumor cells and would not cause damage to normal cells; moreover, the CD38 small molecule inhibitor can specifically inhibit the activity of T-cell receptor molecules; the use of the oncolytic rhabdovirus and the CD38 small molecule inhibitor in combination has significant advantages in safety and efficacy.
5.20200360497COMPOSITIONS AND METHODS FOR PRODUCING DENDRITIC CELLS
US 19.11.2020
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No 16942058 Applicant PrimeVax Immuno-Oncology, Inc. Inventor Bruce W. Lyday

Described herein are compositions and methods for treating a disease, particularly a cancer, with primed dendritic cells recognizing a tumor antigen. The methods may comprise storing, shipping and/or culturing dendritic cells, where the dendritic cells are stored on a hard surface. Lysis protocols are described where the lysis does not result in complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.

6.20200360536TREATMENT OF HEART DISEASE BY DISRUPTION OF THE ANCHORING OF PP2A
US 19.11.2020
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No 16818771 Applicant University of Miami Inventor Michael S. KAPILOFF

The present invention provides a method of treating heart failure with reduced ejection fraction, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the anchoring of PP2A to mAKAPβ. This composition is preferably in the form of a viral based gene therapy vector that encodes a fragment of mAKAPβ to which PP2A binds.

7.WO/2020/230785CELL FUSION-INDUCING VACCINIA VIRUS AND USE THEREOF
WO 19.11.2020
Int.Class A61K 39/002
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
002Protozoa antigens
Appl.No PCT/JP2020/018976 Applicant NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY Inventor NAKAMURA Takafumi
The purpose of the present invention is to provide: a vaccinia virus that induces cell fusion of infected cells; and a method for producing the same. The present invention is a vaccinia virus which lacks the function of the K2L gene or the HA gene, or both the functions of the K2L gene and the Ha gene and is mutated to cause specific cell fusion of infected cells, in which cell fusion of the infected cells occurs to thereby induce cell death.
8.20200360454Gene Editing to Impove Joint Function
US 19.11.2020
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No 16916014 Applicant ORTHOBIO THERAPEUTICS, INC. Inventor Peter J. Millett

The present invention provides compositions and methods for treating joint disorders that are characterized by an inflammatory component. In some aspects, the compositions and methods are to prevent the progression of osteoarthritis and other arthritides and to treat osteoarthritis and other arthritides in a mammalian joint.

9.20200360453METHODS FOR TREATMENT OF SUBJECTS WITH PREEXISTING IMMUNITY TO VIRAL TRANSFER VECTORS
US 19.11.2020
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No 16860729 Applicant Selecta Biosciences, Inc. Inventor Takashi Kei Kishimoto

Provided herein are methods and related compositions for administering viral vectors with synthetic nanocarriers comprising an immunosuppressant to subjects. Such subjects may be subjects with pre-existing immunity against a viral antigen of the viral vector.

10.20200360472COMPOSITIONS AND METHODS FOR TREATING MOTOR NEURON DISEASES
US 19.11.2020
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No 16765914 Applicant The Trustees of Columbia University in the City of New York Inventor Umrao MONANI

The present disclosure provides compositions and methods of treating motor neuron diseases, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). A modulator of a heat shock protein, such as an Hsp70 family member protein, may be used in the present method. Alternatively, a mutant heat shock protein may be used.